New Long-Term skin treatment study seeks to control painful condition

NCT ID NCT07007637

ENROLLING_BY_INVITATION Disease control Sponsor: MoonLake Immunotherapeutics AG Source: ClinicalTrials.gov ↗

Summary

This study aims to learn about the long-term safety and effectiveness of an investigational drug called sonelokimab for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. It is open to about 835 people who have already taken part in a previous related study. The main goal is to see how well people tolerate the drug over a long period and if it continues to help reduce painful skin lumps and improve quality of life.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Clinical Site

Birmingham, Alabama, 35244, United States
Clinical Site

North Little Rock, Arkansas, 72117, United States
Clinical Site

Los Angeles, California, 90404, United States
Clinical Site

Northridge, California, 91325, United States
Clinical Site

Aventura, Florida, 33180, United States
Clinical Site

Coral Gables, Florida, 33134, United States
Clinical Site

Hialeah, Florida, 33012, United States
Clinical Site

Hollywood, Florida, 33021-6746, United States
Clinical Site

Miami, Florida, 33162, United States
Clinical Site

Ocala, Florida, 34471, United States
Clinical Site

Tampa, Florida, 33607, United States
Clinical Site

Macon, Georgia, 31217, United States
Clinical Site

Sandy Springs, Georgia, 30328, United States
Clinical Site

West Dundee, Illinois, 60118, United States
Clinical Site

Columbus, Indiana, 47201, United States
Clinical Site

New Albany, Indiana, 47150, United States
Clinical Site

Plainfield, Indiana, 46168, United States
Clinical Site

Murray, Kentucky, 42071, United States
Clinical Site

Metairie, Louisiana, 70006, United States
Clinical Site

Boston, Massachusetts, 02116, United States
Clinical Site

Canton, Michigan, 48187, United States
Clinical Site

Clarkston, Michigan, 48346, United States
Clinical Site

Waterford, Michigan, 48328, United States
Clinical Site

New Brighton, Minnesota, 55112, United States
Clinical Site

Omaha, Nebraska, 68144, United States
Clinical Site

Las Vegas, Nevada, 89148, United States
Clinical Site

New York, New York, 10003, United States
Clinical Site

New York, New York, 10012, United States
Clinical Site

Boardman, Ohio, 44512, United States
Clinical Site

Dayton, Ohio, 45324, United States
Clinical Site

Murfreesboro, Tennessee, 37130, United States
Clinical Site

Dallas, Texas, 75235, United States
Clinical Site

Dallas, Texas, 75246, United States
Clinical Site

Houston, Texas, 77004, United States
Clinical Site

San Antonio, Texas, 78218, United States
Clinical Site

Mill Creek, Washington, 98012, United States
Clinical Site

Morgantown, West Virginia, 26505, United States
Clinical Site

Leuven, 3000, Belgium
Clinical Site

Sofia, 1407, Bulgaria
Clinical Site

Sofia, 1431, Bulgaria
Clinical Site

Sofia, 1510, Bulgaria
Clinical Site

Edmonton, Alberta, T6H 4J8, Canada
Clinical Site

Winnipeg, Manitoba, R3M 3Z4, Canada
Clinical Site

Fredericton, New Brunswick, E3B 1G9, Canada
Clinical Site

Barrie, Ontario, L4M 7G1, Canada
Clinical Site

Guelph, Ontario, N0B 2J0, Canada
Clinical Site

Markham, Ontario, L3P 1X3, Canada
Clinical Site

Peterborough, Ontario, K9J 5K2, Canada
Clinical Site

Toronto, Ontario, M4E 1R7, Canada
Clinical Site

Montreal, Quebec, H1Y 3L1, Canada
Clinical Site

Québec, Quebec, G1W 4R4, Canada
Clinical Site

Saskatoon, Saskatchewan, S7K 2C1, Canada
Clinical Site

Lyon, 69003, France
Clinical Site

Saint-Priest-en-Jarez, 42270, France
Clinical Site

Halle, Saale, 06108, Germany
Clinical Site

Berlin, 10117, Germany
Clinical Site

Berlin, 10789, Germany
Clinical Site

Bochum, 44791, Germany
Clinical Site

Bochum, 44793, Germany
Clinical Site

Bramsche, 49565, Germany
Clinical Site

Dresden, 01307, Germany
Clinical Site

Erlangen, 91054, Germany
Clinical Site

Frankfurt, 60590, Germany
Clinical Site

Hanover, 30159, Germany
Clinical Site

Langenau, 89129, Germany
Clinical Site

Lübeck, 23538, Germany
Clinical Site

Mahlow, 15831, Germany
Clinical Site

Wuppertal, 42283, Germany
Clinical Site

Pécs, 7632, Hungary
Clinical Site

Chieti, 66013, Italy
Clinical Site

Roma, 00168, Italy
Clinical Site

Torino, 10126, Italy
Clinical Site

Oslo, 0424, Norway
Clinical Site

Krakow, 30-727, Poland
Clinical Site

Poznan, 60-848, Poland
Clinical Site

Warsaw, 00-710, Poland
Clinical Site

Warsaw, 02-507, Poland
Clinical Site

Warsaw, 02-953, Poland
Clinical Site

Wroclaw, 51-503, Poland
Clinical Site

Badalona, 08916, Spain
Clinical Site

Barcelona, 08003, Spain
Clinical Site

Cadiz, 11009, Spain
Clinical Site

Madrid, 28006, Spain
Clinical Site

Madrid, 28046, Spain
Clinical Site

Manises, 46940, Spain
Clinical Site

Málaga, 29010, Spain
Clinical Site

Valencia, 46014, Spain
Clinical Site

Valencia, 46026, Spain

Conditions

Explore the condition pages connected to this study.

HIDRADENITIS SUPPURATIVA